This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (23)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Gastrointestinal/ Upper Foregut  • Surgical Oncology  • Alert me on articles by topic

O. Glehen, MD; V. Schreiber, MD; E. Cotte, MD; A. C. Sayag-Beaujard, MD; D. Osinsky, MD; G. Freyer, MD, PhD; Y. François, MD; J. Vignal, MD; F. N. Gilly, MD, PhD

Arch Surg. 2004;139:20-26.

Hypothesis  The most common cause of palliative resection and recurrence in gastric cancer is peritoneal seeding. This study evaluates the efficacy of intraperitoneal chemohyperthermia after cytoreductive surgery in patients with peritoneal carcinomatosis arising from gastric cancer.

Design  Prospective clinical trial.

Setting  Surgical department at a university academic hospital.

Patients  Forty-nine consecutive patients with peritoneal carcinomatosis treated between January 1, 1989, and February 29, 2000.

Interventions  All patients underwent intraperitoneal chemohyperthermia with mitomycin C (40-60 mg); 21 patients had previously undergone extensive cytoreductive surgery.

Main Outcome Measures  Clinicopathologic factors that affect overall survival rates.

Results  With median follow-up of 99 months, overall median survival was 10.3 months. Two factors were significant independent predictors of survival by multivariate analysis: preoperative ascites (P = .04) and completeness of cancer resection (CCR) by cytoreductive surgery (P<.001). Median survival was 21.3 months for patients with CCR-0 (macroscopic complete resection) or CCR-1 (diameter of residual nodules <5 mm) and 6.1 months for patients with CCR-2 (diameter of residual nodules >5 mm) (P<.001). Four patients survived longer than 5 years.

Conclusions  An aggressive management strategy combining intraperitoneal chemohyperthermia with cytoreductive surgery is effective for patients with peritoneal carcinomatosis arising from gastric cancer. In highly selected patients (good general status, resectable primary tumor, resectable peritoneal carcinomatosis), this therapy may result in long-term survival.

From the Departments of Surgery (Drs Glehen, Osinsky, François, Vignal, and Gilly), Intensive Care (Dr Sayag-Beaujard), and Oncology (Dr Freyer), Centre Hospitalier Lyon-Sud, Pierre Bénite; and the Oncologic Hyperthermia Laboratory-EA Ciblage thérapeutique en Oncologie, Université CB Lyon-1, Oullins (Drs Glehen, Schreiber, Cotte, and Gilly), France.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Systematic Review and Meta-analysis of the Randomized Controlled Trials on Adjuvant Intraperitoneal Chemotherapy for Resectable Gastric Cancer
Yan et al.
Ann. Surg. Oncol. 2007;14:2702-2713.
ABSTRACT | FULL TEXT  

Toxicity and Outcomes Associated with Surgical Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients with Sarcomatosis
Lim et al.
Ann. Surg. Oncol. 2007;14:2309-2318.
ABSTRACT | FULL TEXT  

Outcome of Patients with Known Metastatic Gastric Cancer Undergoing Resection with Therapeutic Intent
Gold et al.
Ann. Surg. Oncol. 2007;14:365-372.
ABSTRACT | FULL TEXT  

Early Postoperative Intraperitoneal Chemotherapy Following Cytoreductive Surgery in Patients with Very Advanced Gastric Cancer
Cheong et al.
Ann. Surg. Oncol. 2007;14:61-68.
ABSTRACT | FULL TEXT  

Toxicity and Quality of Life after Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy
Tuttle et al.
Ann. Surg. Oncol. 2006;13:1627-1632.
ABSTRACT | FULL TEXT  

Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Surface Malignancy: Current Status and Future Directions
Stewart et al.
Ann. Surg. Oncol. 2005;12:765-777.
ABSTRACT | FULL TEXT